Related Experiment Video
Updated: Oct 10, 2025

07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.3K
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
Parneet K Cheema1,2, Shantanu O Banerji3, Normand Blais4
1Medical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Current Oncology (Toronto, Ont.)
|December 13, 2021
Summary
Canadian experts developed consensus recommendations for managing advanced non-small cell lung cancer (NSCLC) with MET alterations. This addresses treatment variations and guides the use of novel MET-targeted therapies for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Disparities in advanced non-small cell lung cancer (NSCLC) management in Canada due to testing and funding variations.
- Emergence of novel mesenchymal-epithelial transition (MET) factor-targeted therapies necessitates standardized treatment approaches.
Keywords:
EGFR resistanceMET amplificationMET exon 14 skipping mutationsMET inhibitorsnon-small cell lung cancerMore Related Videos
Related Concept Videos
Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine
5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

